Overview

Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS)

Status:
Completed
Trial end date:
2015-04-30
Target enrollment:
Participant gender:
Summary
The purpose of this pilot study is to determine whether Maraviroc is effective in the treatment of Kaposi's Sarcoma (KS), when it does not remit with standard antiretroviral drug therapy.
Phase:
Phase 2
Details
Lead Sponsor:
University of California, San Francisco
Collaborators:
Pfizer
ViiV Healthcare
Treatments:
Maraviroc